Member Info for Chris0123

HT - is that before or after Corrie?

Thanks Haywain, even more extraordinary.

Hemogenyx have had 3 patients in treatment for a combined total of 391 days or 1 year & 22 days. Nothing adverse reported so scaremongering about the health of patients is just that. P2 had barely been infused when paediatric approval given by the FDA. Not convinced VS would brush a couple of patient deaths under the carpet before addressing the DCNY Summit. All good news until informed otherwise.

Celtic ".....when the novelty wears off....". What novelty?

Oh, do you mean the infusion of HG-CT-01 where we have one particular patient through 7 months and a third with no sign of original cancer cells after just one month.

Ain't nothing wearing off from this potential life saving therapy. God forbid a family member reads your comment about their loved one's hopes.

Suggest you crawl back under that stone you frequent.

Late in - Tilly looks like we have a sell of 7802 shares & of the buys posted late 3 at 5000 1000 & 1500 = 7550 buys.

Big sell absorbed.

Correct me if I am wrong Tilly, a bow to your knowledge on this.

Have good weekend.

Congratulations Drutor

We were given FDA approval for paediatrics to be included in the clinical trial. This was communicated by RNS on 17th. Next step was IRB (Institutional Review Board). Clearance could be given any time and I am sure no one has sat on their hands for 3 months and 2 days. Treating children with a therapy that shows this amount of promise must be sanctioned soon I'll wager. If it comes it will be communicated straightaway I am sure. Do not rule out that RNS possibility today ahead of Monday.

Remember, even on days there is no RNS - don't forget that this also signifies another succesful survival day. I am finding it difficult to see any downsides with what Hemogenyx are doing right now.

Personally not the least bit interested in hearing the details of people's individual trades or trading strategy. These investors generally operate with very short time lines and that for me means they do not add to the depth of discussion about the medium to long range prospects of the company. Reading these posts adds no value for me. Most invariablty mention another company they are trading (again not interested) and boast about the few quid they made. Carry on doing it of course, (no issue there) but rather you didn't take up space on this discussion medium.

Each to their own I guess.

Vladislav: This is what I have got, this is how good it is, tell me what are you prepared to pay me for it.

Investor: Jeepers Vladislav, where have you been hiding. How many billions do you want?

Politician: There's a lot of big shots swarming around Vladislav - better get even more US billions so we don't get shafted down the road by a foreign state.

Win Win!

Sorry that should say ..when Patient 2 had barely been infused...Oops!

It is worth looking at the 28 day safety report for EACH of the 3 Patients. Compare and contrast:

Patient 1: "Early signs of efficacy are encouraging"

Paitent 2: "Encouragingly, early indications of clinical efficay are evident"

Patient 3: "Importantly, early indications of clinical efficacy have been observed. Preliminary assessment shows that original AML cells were NOT (emphasis) detectable...."

Arguably, either Vladislav was holding back initially, has grown in confidence in his reporting back or Patient 3 is doing even better than the first 2 paitents and they are over 4 months and 7 months survival respectively. Each patient better than the next. Great outlook for P3. No wonder they applied for paediatrics , and this application was made when Patient 1 had barely been infused!! Hold on tight to your shares I say.

SP finish of £15 would be nice going into Wednesday. We have to hear of progress in an RNS tomorrow. If VS waits for the Summit the time zone will mean we have lost Thursday too . No value in that. Just do the presentation knowing that when you stand there your SP already reflects what you are presenting to the Summit. With bouyant trading carried right through Thursday. We'll not see £14.50 SP again after the RNS so FOMO is today!

RNS has to be tomoorow.

Good luck to you and your family Bline. Well done on keeping the faith. You and many others have been sorely challenged.

Could always do with a Tiger in our tank !

The DCNY Summit - "This is not a conference of thousands, but a boutique convening where real conversations unfold and trust is built"

For a "...select group of influential leaders shaping .....innovation at the highest levels"

We should not underestimate the impact an invitation to attend is contributing to the growth in the share price. Likely, the big share buyers we have seen lately know the value of this invitation too.

JHFH - I get the feeling that for a few reasons we may see an RNS on Tuesday.

1.The early issues with preparing the P3 may make them dot the i's and cross the t's a tad (each patient is unique) ; 2. The weekend interrupts a bit and whilst the patient may transition through 2 more days it's not necessarily a full shift the whole weekend by the medical staff and report writers.

Hope nobody bails on Monday if there is not an RNS just sharing thoughts on why there might not be. That said, I really do hope it is Monday. Glad to be wrong! It seems the shorters are playing fast and loose that it's not Monday. £14 Monday or Tuesday will do. GLA

RNS - 20th January 2020 HEMO CAR-T update in vivo. CAR-T indicates anti cancer activity in humanized mouse model.

Spare a moment to think about how VS is feeling right now. Then, another moment for the long term holders, who through thick and thin, backed him all the way.

Like the sound of that Checkricky

RNS - "Hemogenyx will present its clinical progress and its pipeline as part of the Summit's (emphasis) CURATED COMPANY SHOWCASE".

It's so easy to read over the meaning what does "curated company showcase" really mean.

According to AI - A curated company showcase is an event or platform that features a carefully selected group of businesses to an audience of investors, partners, or potential customers. The "curation" involves a selection process to ensure the showcased companies are high-potential or relevant to the event's theme, offering benefits such as exclusive access to innovation, investment opportunities, and networking with key players."

Very interested to hear what VS says about the "pipeline" too.

Our 3 patients combined have totalled just shy of a year in treatment. No reported issues or side effects. Fantastic record. P2 and P3 must delighted where P1 is at and very hopeful for their future and the future of their families.

We just need these results to continue and we'll see off the diseased shorters too, starting with RMc.

Don't want to know about the health of any other shares on here, just our patitents thanks.